|
WO2019134866A1
|
|
Chimeric antigen receptors containing optimal spacer region
|
|
WO2017108817A1
|
|
Stable integration of sin transfer vectors
|
|
US2017252435A1
|
|
Combination
|
|
EP3575315A1
|
|
Chimeric antigen receptors
|
|
CA2848939A1
|
|
Viral vectors purification system
|
|
WO2012076452A1
|
|
Release of endogenous il7 by the infusion of genetically modified cells for immune reconstitution
|
|
WO2012045719A2
|
|
New vascular targeting peptides
|
|
CA2809447A1
|
|
Semi-stable production of lentiviral vectors
|
|
RS53344B
|
|
Stable production of lentiviral vectors
|
|
AU2009248105A1
|
|
Conjugates for the treatment of mesothelioma
|
|
GB0708864D0
|
|
Cytokine Conjugate
|
|
GB0624308D0
|
|
Combination product
|
|
AU2006238617A1
|
|
HIV Vif mutants
|
|
AU2005317684A1
|
|
Conjugation product
|
|
GB0510888D0
|
|
Hiv vif
|
|
GB0507003D0
|
|
Therapeutic
|
|
GB0504770D0
|
|
HIV Vif
|
|
GB0413702D0
|
|
Thymidine kinase
|
|
GB0410130D0
|
|
Cell preparation
|
|
GB0224442D0
|
|
A delivery system
|
